Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Pharmaceutical Strategic Initiatives® announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.  The symposium titled Anticoagulation Management at the Crossroads –Addressing the Developments Impacting Future Decades was sponsored by Research Triangle Park, NC based Pharmaceutical Strategic Initiatives, LLC.  This interactive symposium was organized in collaboration with the Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, the North American Thrombosis Forum (NATF), and the International Union of Angiology (IUA).

Professor Jawed Fareed, Ph.D., Professor of Pathology and Pharmacology, Director of Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, was the chair for the program which also included presentations regarding emerging topics in anticoagulation management and for patients at risk of thrombosis and related disorders.  The distinguished faculty representing leading international institutions included Professor Samuel Goldhaber, MD from Brigham and Women's Hospital in Boston, MA, Professor Jeanine Walenga, Ph.D. from Loyola University Medical Center in Maywood, IL, Professor Benjamin Brenner from Rambam Health Care Campus in Haifa, Israel, Massimo Iacobelli, M.D. from Gentium, S.P.A. in Como Italy, Professor Selim Corbacioglu, M.D. from Children's Hospital Regensburg in Regensburg, Germany, Ilene Sussman, Ph.D. from the North American Thrombosis Forum in Boston, MA and Charles Carter, Pharm.D. from Pharmaceutical Strategic Initiatives, LLC in Research Triangle Park, NC.  The topics presented and discussed covered new treatment modalities for the prevention and treatment of patients at risk for thrombotic and vascular disorders including atrial fibrillation, acute coronary syndromes, diabetes, cancer and transplantation associated venous occlusive disorder.  In addition, the panel considered recent worldwide regulatory developments that are changing the landscape of anticoagulation therapy which includes the introduction of newer oral anticoagulants and generic versions of branded drugs.  The symposium was very well attended and a number of the hematology professionals who attended expressed their appreciation of this timely and informative session.

SOURCE Pharmaceutical Strategic Initiatives LLC